{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:17:19Z","timestamp":1789503439696,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00280-019-03888-1","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T08:02:52Z","timestamp":1560585772000},"page":"599-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients"],"prefix":"10.1007","volume":"84","author":[{"given":"Xuan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-8813","authenticated-orcid":false,"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"3888_CR1","unstructured":"GLOBOCAN2018: Estimated cancer incidence, mortality and prevalence worldwide in 2018. \n                    http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx\n                    \n                  . Accessed 2019"},{"issue":"12","key":"3888_CR2","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1016\/S1470-2045(13)70436-4","volume":"14","author":"L Shen","year":"2013","unstructured":"Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT (2013) Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 14(12):e535\u2013e547. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70436-4","journal-title":"Lancet Oncol"},{"issue":"2","key":"3888_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a058778","volume":"5","author":"B Glimelius","year":"1994","unstructured":"Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5(2):189\u2013190","journal-title":"Ann Oncol"},{"issue":"3","key":"3888_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71(3):587\u2013591","journal-title":"Br J Cancer"},{"issue":"Suppl 7","key":"3888_CR5","doi-asserted-by":"publisher","first-page":"vii173","DOI":"10.1093\/annonc\/mdq295","volume":"21","author":"I Brana","year":"2010","unstructured":"Brana I, Tabernero J (2010) Cardiotoxicity. Ann Oncol 21(Suppl 7):vii173\u2013vii179. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdq295","journal-title":"Ann Oncol"},{"key":"3888_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.med.57.121304.131240","volume":"57","author":"ET Yeh","year":"2006","unstructured":"Yeh ET (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57:485\u2013498. \n                    https:\/\/doi.org\/10.1146\/annurev.med.57.121304.131240","journal-title":"Annu Rev Med"},{"issue":"4","key":"3888_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R 3rd (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7(4):214\u2013220","journal-title":"Curr Cardiol Rev"},{"issue":"12","key":"3888_CR8","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1586\/14737140.7.12.1763","volume":"7","author":"PJ Perik","year":"2007","unstructured":"Perik PJ, de Korte MA, van Veldhuisen DJ, Gietema JA, Sleijfer DT, de Vries EG (2007) Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev Anticancer Ther 7(12):1763\u20131771. \n                    https:\/\/doi.org\/10.1586\/14737140.7.12.1763","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"3888_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","volume":"8","author":"MW Saif","year":"2009","unstructured":"Saif MW, Shah MM, Shah AR (2009) Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 8(2):191\u2013202. \n                    https:\/\/doi.org\/10.1517\/14740330902733961","journal-title":"Expert Opin Drug Saf"},{"issue":"9604","key":"3888_CR10","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604):2011\u20132019. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)61865-0","journal-title":"Lancet"},{"issue":"6","key":"3888_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF03006439","volume":"17","author":"K Saito","year":"2003","unstructured":"Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y (2003) Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med 17(6):481\u2013488","journal-title":"Ann Nucl Med"},{"issue":"18","key":"3888_CR12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"3888_CR13","unstructured":"Common Terminology Criteria for Adverse Events. \n                    http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_5.0\n                    \n                  . Accessed 2019"},{"issue":"20","key":"3888_CR14","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","volume":"33","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S (2012) Third universal definition of myocardial infarction. Eur Heart J 33(20):2551\u20132567. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehs184","journal-title":"Eur Heart J"},{"issue":"8","key":"3888_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975. \n                    https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"3888_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 66(4):309\u2013325. \n                    https:\/\/doi.org\/10.3322\/caac.21341","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"3888_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435\u20131442. \n                    https:\/\/doi.org\/10.1200\/jco.2007.13.9378","journal-title":"J Clin Oncol"},{"issue":"6","key":"3888_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):490\u2013499. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(13)70102-5","journal-title":"Lancet Oncol"},{"key":"3888_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","volume":"76","author":"JJ Kwakman","year":"2017","unstructured":"Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ (2017) Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer (Oxf Engl 1990) 76:93\u201399. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.02.009","journal-title":"Eur J Cancer (Oxf Engl 1990)"},{"issue":"4","key":"3888_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000471759","volume":"12","author":"M Osman","year":"2017","unstructured":"Osman M, Elkady M (2017) A prospective study to evaluate the effect of paclitaxel on cardiac ejection fraction. Breast Care 12(4):255\u2013259. \n                    https:\/\/doi.org\/10.1159\/000471759","journal-title":"Breast Care"},{"issue":"4_suppl","key":"3888_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1200\/JCO.2017.35.4_suppl.553","volume":"35","author":"G Chen","year":"2017","unstructured":"Chen G, Peng J, Dong C, Qiu M, Wang C, Li Hw YuH, Zhang M, Zhao Q, Zhu B, Zhang J, Li W, Wang F, Wu Q, Yuan Y, Zhou W-H (2017) Cardiotoxicity in Chinese cancer patients treated with 5-fluorouracil or capecitabine: a multicenter prospective observational study. J Clin Oncol 35(4_suppl):553. \n                    https:\/\/doi.org\/10.1200\/jco.2017.35.4_suppl.553","journal-title":"J Clin Oncol"},{"issue":"8","key":"3888_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","volume":"39","author":"A Polk","year":"2013","unstructured":"Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL (2013) Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 39(8):974\u2013984. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.005","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3888_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134(1):75\u201382. \n                    https:\/\/doi.org\/10.1007\/s00432-007-0250-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"3888_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","volume":"58","author":"SA Jensen","year":"2006","unstructured":"Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58(4):487\u2013493. \n                    https:\/\/doi.org\/10.1007\/s00280-005-0178-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3888_CR25","first-page":"430","volume":"62","author":"MA Khan","year":"2012","unstructured":"Khan MA, Masood N, Husain N, Ahmad B, Aziz T, Naeem A (2012) A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. JPMA J Pak Med Assoc 62(5):430\u2013434","journal-title":"JPMA J Pak Med Assoc"},{"issue":"3","key":"3888_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/annonc\/mdf108","volume":"13","author":"E Van Cutsem","year":"2002","unstructured":"Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B (2002) Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13(3):484\u2013485","journal-title":"Ann Oncol"},{"issue":"1","key":"3888_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/bjc.1998.12","volume":"77","author":"M Arellano","year":"1998","unstructured":"Arellano M, Malet-Martino M, Martino R, Gires P (1998) The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 77(1):79\u201386","journal-title":"Br J Cancer"},{"issue":"5","key":"3888_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.bjc.6601224","volume":"89","author":"Y Yamada","year":"2003","unstructured":"Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S (2003) Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89(5):816\u2013820. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6601224","journal-title":"Br J Cancer"},{"issue":"4","key":"3888_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdr348","volume":"23","author":"C Serrano","year":"2012","unstructured":"Serrano C, Cortes J, De Mattos-Arruda L, Bellet M, Gomez P, Saura C, Perez J, Vidal M, Munoz-Couselo E, Carreras MJ, Sanchez-Olle G, Tabernero J, Baselga J, Di Cosimo S (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23(4):897\u2013902. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr348","journal-title":"Ann Oncol"},{"issue":"1","key":"3888_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12094-016-1508-y","volume":"19","author":"J Gavila","year":"2017","unstructured":"Gavila J, Segui MA, Calvo L, Lopez T, Alonso JJ, Farto M, Sanchez-de la Rosa R (2017) Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clin Transl Oncol 19(1):91\u2013104. \n                    https:\/\/doi.org\/10.1007\/s12094-016-1508-y","journal-title":"Clin Transl Oncol"},{"issue":"26","key":"3888_CR31","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","volume":"34","author":"C Guenancia","year":"2016","unstructured":"Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, Zeller M, Rochette L, Cottin Y, Vergely C (2016) Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 34(26):3157\u20133165. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.4846","journal-title":"J Clin Oncol"},{"issue":"21","key":"3888_CR32","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.3748\/wjg.v21.i21.6631","volume":"21","author":"SH Jeong","year":"2015","unstructured":"Jeong SH, Kim YW, Yu W, Lee SH, Park YK, Park SH, Jeong IH, Lee SE, Park Y, Lee YJ (2015) High morbidity in myocardial infarction and heart failure patients after gastric cancer surgery. World J Gastroenterol 21(21):6631\u20136638. \n                    https:\/\/doi.org\/10.3748\/wjg.v21.i21.6631","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3888_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","volume":"11","author":"S Mantarro","year":"2016","unstructured":"Mantarro S, Rossi M, Bonifazi M, D\u2019Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L (2016) Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 11(1):123\u2013140. \n                    https:\/\/doi.org\/10.1007\/s11739-015-1362-x","journal-title":"Intern Emerg Med"},{"issue":"2\u20133","key":"3888_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.disamonth.2005.03.010","volume":"51","author":"AY Lee","year":"2005","unstructured":"Lee AY (2005) Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Month DM 51(2\u20133):150\u2013157. \n                    https:\/\/doi.org\/10.1016\/j.disamonth.2005.03.010","journal-title":"Dis Month DM"},{"issue":"17","key":"3888_CR35","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","volume":"18","author":"BA Hutten","year":"2000","unstructured":"Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18(17):3078\u20133083. \n                    https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3078","journal-title":"J Clin Oncol"},{"issue":"15","key":"3888_CR36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"34","author":"TM Suter","year":"2013","unstructured":"Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34(15):1102\u20131111. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehs181","journal-title":"Eur Heart J"},{"issue":"1","key":"3888_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14\u201325. \n                    https:\/\/doi.org\/10.1093\/jnci\/djp440","journal-title":"J Natl Cancer Inst"},{"key":"3888_CR38","doi-asserted-by":"publisher","first-page":"671232","DOI":"10.1155\/2015\/671232","volume":"2015","author":"J Sulpher","year":"2015","unstructured":"Sulpher J, Mathur S, Graham N, Crawley F, Turek M, Johnson C, Stadnick E, Law A, Wentzell J, Dent S (2015) Clinical experience of patients referred to a multidisciplinary cardiac oncology clinic: an observational study. J Oncol 2015:671232. \n                    https:\/\/doi.org\/10.1155\/2015\/671232","journal-title":"J Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03888-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T23:05:08Z","timestamp":1592089508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03888-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3888"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03888-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}